LDS/Medical Tests/TGFB3 Gene Mutation Analysis

TGFB3 Gene Mutation Analysis

The TGFB3 gene, located on the long (q) arm of chromosome 14 at position 24.3 encodes transforming growth factor beta-3 (TGFβ3). TGFβ3 is a cytokine protein, involved in cell differentiation, embryogenesis, and development. It belongs to the transforming growth factor beta superfamily, which includes the TGF-β family, bone morphogenetic protein (BMPs), growth and differentiation factors (GDFs), inhibins and activins. TGFβ3 is a multifunctional protein that regulates molecules involved in cellular adhesion and extracellular matrix (ECM) formation during the process of palate development. The TGF-β3 protein also plays a role in the formation of blood vessels, the regulation of muscle tissue and body fat development, wound healing, and immune system function. TGFβ3 acts by binding to TGF-beta receptors (TGFBR1 and TGFBR2), which then produce an intracellular signal. Mutation in TGFB3 gene can cause Loeys-Dietz syndrome type V and Arrhythmogenic right ventricular dysplasia 1.

Loeys-Dietz syndrome type V is an autosomal dominant disorder in which patients may have cleft palate, bifid uvula, tall stature, hypertelorism, arachnodactyly, pectus deformity, clubfoot, osteoarthritis, aortic root aneurysm, arterial aneurysms, arterial tortuosity, arterial dissection, bicuspid aortic valve, mitral valve insufficiency, and striae. Truncating variants (nonsense, frameshifts) and missense variants are the mutations ost commonly seen in TGFB3 in this disorder. Patients with LDS are at increased risk of aortic aneurysm and dissection, inercranial aneurysms and hemorrhage, and an increased incidence of pregnancy-related complications including uterine rupture and death. Mutations in TGFB2 gene cause the production of a TGFβ-2 protein that results in a gain-of-function in the TGF-β signaling pathway. This excessive signaling pathway disrupts development of connective tissue and various body systems and leads to the signs and symptoms of Loeys-Dietz syndrome type V.

Arrhythmogenic right ventricular dysplasia 1 (ARVC/D) is a disease of the heart muscle primarily affecting the right ventricle. This disease is typically caused by missense or nonsense mutations in TGFB3 and is inherited in an autosomal dominant pattern with age- and gender-dependent penetrance. It is characterized by myocardial atrophy, fibrofatty replacement of the ventricular myocardium and inflammatory infiltrates. patients with ARVC/D are at risk for ventricular arrhythmias, recurrent syncope, seizures and sudden death after physical or emotional stress. It is responsible for ~20% of sudden cardiac death in young adults and has an incidence of 1/1000 to 1/5000 people worldwide with a higher prevalence in men than women.

  • For the diagnosis of TGFB3-associated Loeys-Dietz syndrome type V and Arrhythmogenic right ventricular dysplasia 1
  • To identify carriers of familial TGFB3 mutations by predictive testing in family members.
  • For the prenatal genetic testing in individuals at risk of arrhythmogenic right ventricular dysplasia 1 or Loeys-Dietz syndrome type V
  • To assist with prognosis, clinical management and surveillance for disease features based on the genetic variant involved

Positive: Mutation or pathogenic variant in TGFB3 gene. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.

Negative for mutation or pathogenic variant in TGFB3 gene

Sequence analysis by next generation sequencing or bi-directional sequencing. TGFB3 gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.

Whole blood (EDTA), amniotic fluid (prenatal test).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 weeks
  • Frozen: Unacceptable
Cardiac panel, TGFBR1, TGFBR2, SMAD3, TGFB2, FBN1, ACTA2, PKP2, DSP, DSG2 and MYH11 mutation analysis for aortic aneurysms and aortic dissections, Comprehensive Skeletal Dysplasias and Disorders Panel, Ehlers-Danlos Syndrome Panel, Marfan Syndrome Panel, Comprehensive Growth Disorders / Skeletal Dysplasias and Disorders Panel, Craniosynostosis Panel, Aortopathy Panel, TGFB3 Sequencing and Deletion/Duplication analysis.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login